$6.75 Billion is the total value of Avoro Capital Advisors LLC's 41 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HZNP | HORIZON THERAPEUTICS PLC | $763,980,000 | -4.1% | 7,000,000 | 0.0% | 11.33% | -4.9% | |
| ALNY | ALNYLAM PHARMACEUTICALS INC | $221,353,600 | -15.7% | 1,105,000 | 0.0% | 3.28% | -16.4% | |
| MRTX | MIRATI THERAPEUTICS INC | $206,555,535 | -17.9% | 5,555,555 | 0.0% | 3.06% | -18.6% | |
| XENE | XENON PHARMACEUTICALS INC | $175,371,000 | -9.2% | 4,900,000 | 0.0% | 2.60% | -9.9% | |
| CBAY | CYMABAY THERAPEUTICS INC | $89,816,000 | +39.1% | 10,300,000 | 0.0% | 1.33% | +38.0% | |
| SNDX | SYNDAX PHARMACEUTICALS INC | $55,968,000 | -17.0% | 2,650,000 | 0.0% | 0.83% | -17.7% | |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | $42,892,200 | -4.4% | 7,020,000 | 0.0% | 0.64% | -5.1% | |
| KURA | KURA ONCOLOGY INC | $37,974,150 | -1.5% | 3,105,000 | 0.0% | 0.56% | -2.3% | |
| MNKD | MANNKIND CORP | $37,310,000 | -22.2% | 9,100,000 | 0.0% | 0.55% | -22.9% | |
| GLUE | MONTE ROSA THERAPEUTICS INC | $33,691,750 | +2.4% | 4,325,000 | 0.0% | 0.50% | +1.4% | |
| MRSN | MERSANA THERAPEUTICS INC | $31,030,500 | -29.9% | 7,550,000 | 0.0% | 0.46% | -30.4% | |
| RARE | ULTRAGENYX PHARMACEUTICAL INC | $30,075,000 | -13.4% | 750,000 | 0.0% | 0.45% | -14.1% | |
| MARINUS PHARMACEUTICALS INC | $21,735,000 | +73.4% | 3,150,000 | 0.0% | 0.32% | +72.2% | ||
| AADI BIOSCIENCES INC | $20,629,670 | -43.6% | 2,849,402 | 0.0% | 0.31% | -44.0% | ||
| PMVP | PMV PHARMACEUTICALS INC | $14,596,200 | -45.2% | 3,060,000 | 0.0% | 0.22% | -45.7% | |
| FENC | FENNEC PHARMACEUTICALS INC | $9,984,000 | -13.3% | 1,200,000 | 0.0% | 0.15% | -14.0% | |
| TANGO THERAPEUTICS INC | $6,478,000 | -45.5% | 1,640,000 | 0.0% | 0.10% | -46.1% | ||
| IO BIOTECH INC | $3,844,501 | -18.7% | 2,055,883 | 0.0% | 0.06% | -19.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.